Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

T. Nakagami · the DECODA Study Group

Steno Diabetes Centre, Gentofte, Denmark

Abstract

Aims/hypothesis. The study was done to assess how well fasting and 2-h plasma glucose (FPG, 2-h PG) after a 75-g OGTT predict cardiovascular disease (CVD) and all-cause mortality in Asian subjects.

Methods. People ($n=6817$) of Japanese and Asian Indian origin from five prospective studies in five countries were monitored for 5 to 10 years. Hazard ratios for death from all causes and CVD were estimated using Cox proportional hazard models, adjusting for FPG, 2-h PG and established risk factors.

Results. Multivariate Cox regression analysis showed that an increase in FPG from 7.0 to 8.0 mmol/l (increase of 0.76 SD) increased relative risk (95% CI) by 1.14 (1.05–1.25) for all-cause and 1.24 (1.10–1.39) for CVD mortality. An increase in 2-h PG from 9.0 to 11.9 mmol/l (0.76 SD) increased relative risks by 1.29 (1.18–1.41) and 1.35 (1.19–1.54). Inclusion of 2-h

PG in the FPG model improved the predictive value ($p<0.001$), whereas FPG did not influence the predictive value of 2-h PG ($p>0.10$). In a model containing FPG and 2-h PG, hazards ratios for 2-h PG in subjects with IGT or diabetes were 1.35 (1.03–1.77) or 3.03 (2.18–4.21) for all-cause and 1.27 (0.86–1.88) or 3.39 (2.14–5.37) for CVD mortality, compared with normal subjects. The respective hazards ratio for FPG in subjects with IFG or diabetes were 0.94 (0.68–1.31) or 0.88 (0.59–1.32) for all-cause and 1.05 (0.67–1.65) or 0.88 (0.51–1.51) for CVD mortality, compared with normal subjects.

Conclusions/interpretation. For prediction of premature death, 2-h PG was superior to FPG in several Asian populations. [Diabetologia (2004) 47:385–394]

Keywords Fasting glucose · Post-challenge glucose · Mortality · Cardiovascular disease · Asian Indians · Japanese · Diagnostic criteria

Received: 2 June 2003 / Revised: 5 September 2003
Published online: 18 February 2004
© Springer-Verlag 2004

T. Nakagami (✉)
Steno Diabetes Centre, Niels Steensens Vej 2,
2820 Gentofte, Denmark
E-mail: nakagami@dmc.twmu.ac.jp

Abbreviations: CVD, Cardiovascular disease · DECODE, Diabetes Epidemiology: Collaborative Analysis Of Diagnostic Criteria in Europe · FPG, fasting plasma glucose · 2-h PG, 2-hour plasma glucose · DECODA, Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia · WHO, World Health Organization · IGR, impaired glucose regulation

This article was written on behalf of the International Diabetes Epidemiology Group

Members of the DECODA Study Group are listed at the end of the paper

The association between hyperglycaemia and the risk of microvascular complications [1, 2], myocardial infarction [1, 2, 3], stroke [4], macrovascular mortality [5, 6, 7] and all-cause mortality [1, 7, 8, 9, 10, 11, 12] is well known in patients with Type 2 diabetes. A meta-regression analysis of 20 studies among non-diabetic men reported a graded relation between glucose concentration and cardiovascular disease (CVD) events, with blood glucose concentrations below the threshold for diabetes nevertheless associated with CVD events [13]. Several cohort studies [14, 15, 16, 17, 18, 19], including some on Asian populations, have indicated that people with pre-diabetic conditions have an increased risk of all-cause mortality and CVD morbidity and mortality.

The Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe (DECODE) study has confirmed that people with IGT or IFG have a sig-

nificantly increased risk of death from CVD and all causes, and that this risk ranks between those of normal and diabetic groups [20, 21]. The DECODE data also showed that the 2-h plasma glucose (2-h PG) concentration after a 75-g OGTT is an independent predictor of CVD mortality, while prediction of CVD death on the basis of fasting plasma glucose (FPG) is largely due to correlation with 2-h PG concentrations. Similar results for Asian populations are scarce, but much needed due to the rapidly increasing prevalence of diabetes in Asia [22, 23].

To assess the relationship between glucose concentrations and mortality, together with other established risk factors in Asian populations, we analysed the follow-up data from the Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia (DECODA) Study [24]. The specific aims of this analysis were: (i) to assess to what degree FPG and 2-h PG predict all-cause and CVD mortality, taking account of other established CVD risk factors; and (ii) to identify glucose categories associated with excess all-cause and CVD mortality.

Subjects and methods

Participants. The study populations and methods used to recruit participants in the DECODA study have already been described [24, 25, 26]. Briefly, centres which had carried out studies on the prevalence of diabetes using a standard 75-g OGTT with FPG and 2-h PG in adult Asian populations were identified and invited to participate in the DECODA study. Data on FPG and 2-h PG concentrations and some other variables were transferred to the Diabetes and Genetic Epidemiology Unit of the National Public Health Institute in Helsinki, Finland, for pooled data analysis. This analysis included studies with prospective data on cause-specific mortality and all required confounding variables (height, weight, systolic and diastolic blood pressure, total serum cholesterol, smoking status).

A total of five centres contributed to the pooled analysis (Table 1). Of these three included Japanese populations: Funagata, Japan (Funagata Diabetes Study) [19], Seattle, USA (Japanese American Community Diabetes Study) [27, 28], Sao Paulo, Brazil (Japanese Brazilian Diabetes Study) [29]. Two included Asian Indian populations: Fiji and Mauritius [30, 31]. Of the 6817 subjects (3121 men and 3696 women) aged 30 to 89 years, 511 (7.5%) had previously been diagnosed with diabetes. The number of deaths from all causes was 381 among subjects without previously diagnosed diabetes and 107 among those previously diagnosed with diabetes. The corresponding numbers for CVD deaths were 182 and 58. The median duration of follow-up was 5.0 years. People without previously diagnosed diabetes contributed 37 026 person-years of follow-up, those previously diagnosed with diabetes contributed 3208 person-years. The follow-up ascertainment rate ranged from 92 to 100%.

Vital status and underlying cause of death were determined for each deceased participant from death certificates. This was done independently for each centre. Individuals who had emigrated and whose vital status could not be verified were treated as censored cases at the time of emigration or loss. The underlying cause of death was classified according to the International Classification of Diseases, 9th Revision, with codes 401 to 448 considered to be CVD [32].

Table 1. Surveys analysed for this DECODA study

Study cohort (ethnicity)	Numbers	Men (%)	Follow-up ascertainment rate (%)	Median years [range]		Number of deaths (%)		Mortality per 1000 person-years (95% CI) ^a	
				Age at baseline	Duration of follow-up	All causes	CVD	All causes	CVD
Funagata, Japan (Japanese)	2154	43	100	59 [35–89]	4.5 [0.2–8.5]	102 (4.7)	37 (1.7)	6.3 (6.2–6.3)	2.6 (2.5–2.6)
Sao Paulo, Brazil (Japanese Brazilians)	573	38	99	58 [40–81]	6.7 [0.6–8.5]	49 (8.5)	26 (4.5)	9.5 (9.4–9.6)	5.1 (5.0–5.2)
Seattle, USA (Japanese Americans)	608	54	92	55 [34–75]	8.6 [0.4–16.5]	75 (11.4)	44 (6.7)	10.0 (10.0–10.1)	5.8 (5.8–5.9)
Mauritius (Asian Indians)	2676	47	99	45 [30–74]	5.0 [0.2–5.0]	142 (5.3)	68 (2.5)	18.3 (18.2–18.4)	8.9 (8.8–8.9)
Fiji (Asian Indians)	806	47	95	45 [30–88]	10.6 [0.2–11.4]	120 (14.2)	65 (7.7)	28.0 (27.8–28.2)	13.2 (13.1–13.3)
Total	6817	46	99	50 [30–89]	5.0 [0.2–16.5]	488 (7.0)	240 (3.5)	13.2 (13.2–13.3)	6.8 (6.8–6.8)

^a Mortality was age-standardised using the world standard population of subjects of 40 to 74 years of age

Subjects clinically diagnosed as diabetes before the survey were classified as previously diagnosed cases. Subjects without previously diagnosed diabetes were placed in three glucose categories, firstly on the basis of 2-h PG criteria alone (11.1 mmol/l or more; 7.8–11.0 mmol/l; less than 7.8 mmol/l), and secondly on the basis of FPG concentrations alone (7.0 mmol/l or more; 6.1–6.9 mmol/l; and less than 6.1 mmol/l). Further classification of glucose category was done according to the 1999 World Health Organization (WHO) criteria [33], i.e. (i) normal: FPG less than 6.1 mmol/l and 2-h PG less than 7.8 mmol/l; (ii) impaired glucose regulation (IGR): FPG 6.1–6.9 mmol/l and/or 2-h PG 7.8–11.0 mmol/l; (iii) FPG diabetes: FPG 7.0 mmol/l or more; (iv) isolated post-challenge glucose diabetes: FPG less than 7.0 mmol/l and 2-h PG 11.1 mmol/l or more; (v) previously diagnosed diabetes.

All participants gave informed consent to participate in the study according to the Declaration of Helsinki or other ethical standards relevant to the time when data collection was conducted.

Statistical methods. The age-standardised prevalence of glucose intolerance (IGR, IFG and/or IGT, and diabetes) and the age-standardised CVD and all-cause mortality were calculated using 5-year age intervals with direct standardisation to the world standard population [34]. Analysis of variance was used to compare means of fasting glucose and/or 2-h PG concentrations at baseline among subjects without previously diagnosed diabetes between five cohorts. Adjusted means of age, BMI, blood pressure and total cholesterol were calculated using analysis of covariance, and compared with a given reference group by pair-wise comparison.

Hazard ratios for CVD and all-cause mortality were estimated in subjects without previously diagnosed diabetes using the multivariate Cox proportional hazards models for each of the five cohorts, adjusting for age, sex, BMI, systolic blood pressure, total cholesterol, plasma glucose (fasting or 2-h) and smoking status (coded as non-smokers, ex-smokers and current smokers). BMI was calculated as weight (kg) divided by height² (m). In participants without previously diagnosed diabetes FPG and 2-h PG concentrations were natural-logarithmically transformed and used in the models as a continuous variable. The individual hazards ratios of each Cox model were pooled into an overall hazards ratio according to the Fleiss method [35]. A fixed rather than a random effects approach was chosen because the Q statistic for measuring study-to-study variation in effect size was not statistically different from zero [35]. Individual and the overall standardised hazards ratios, corresponding to a standard deviation increase of 1 in the natural-logarithmically transformed glucose concentrations, were reported with their 95% CI. To make results of FPG and 2-h PG compatible, hazard ratios for a standard deviation increase of 1 in natural-logarithmically transformed FPG and 2-h PG values were calculated and reported.

The relative risks for CVD and all-cause mortality, the exponential function of the beta coefficient and their 95% CIs were estimated for the three glucose categories according to FPG and 2-h PG as described above, using the multivariate Cox proportional hazards model adjusting for age, sex, cohort, BMI, systolic blood pressure, cholesterol and smoking status. A Wald test was done to examine the trend in the risk of events, by coding the three glucose categories linearly. A chi square log-likelihood ratio test was carried out to test the prediction of death by FPG, adjusted for 2-h PG, and the predictive value for 2-h PG, adjusted for FPG. A similar Cox model was used to estimate the relative risk of CVD and all-cause mortality for the five WHO glucose categories described above.

SPSS for Windows version 11.0 (Chicago, Ill., USA) was used for statistical analyses. The *p* values were based on two-sided tests and results were regarded as statistically significant at a *p* value of less than 0.05.

Results

Among subjects without previously diagnosed diabetes, the baseline mean level of 2-h PG was lower in the Funagata Study than in other studies ($p < 0.05$), while the baseline mean level of FPG was higher in the Mauritius and the Fiji Study than in the Funagata Study ($p < 0.05$, Table 2).

The age-standardised prevalence of all diabetes categories among subjects who were 40 to 74 years of age was lowest in the Funagata Study (6.6%), followed by the Sao Paulo (Japanese Brazilian) Study (18.7%), the Mauritius Study (22.3%), the Seattle (Japanese American) Study (22.9%) and the Fiji Study (30.8%) (Table 2). The lowest prevalence of IGR was found in the Funagata Study (10.4%), followed by the Sao Paulo (Japanese Brazilian) Study (18.0%), the Fiji Study (18.8%), the Mauritius Study (22.1%) and the Seattle (Japanese American) Study (32.9%).

Baseline mean values of BMI for each glucose category did not differ between the studies (Table 2). However, with the exception of total cholesterol in the Fiji Study, baseline mean values of CVD risk factors were lower in the Funagata Study than in other studies for each glucose category.

Age-standardised all-cause and CVD mortality among subjects of 40 to 74 years of age was lower in the three Japanese studies than in the two Asian Indian studies (Table 1). Age-standardised all-cause and CVD mortality rates ranged from 6.3 and 2.6 respectively per 1000 person-years in the Funagata Study to 28.0 and 13.2 respectively per 1000 person-years in the Fiji Study. In this age group the overall standardised mortality rate was 13.3 per 1000 person-years for all-causes and 6.8 per 1000 person-years for CVD.

There were no major cohort and ethnic variations in beta coefficients for prediction of death from FPG and 2-h PG, as the statistic Q values varied from 2.9 to 7.9, 4df, (all *p* values > 0.05). There was no statistically significant evidence against pooling the data. Mortality from all causes and CVD increased, and significantly, with increasing 2-h PG and/or FPG, adjusting for age, sex, BMI, systolic blood pressure, total cholesterol and smoking status among subjects without previously diagnosed diabetes (Figs. 1, 2). The standardised hazards ratio corresponding to a standard deviation increase of 1 in log-transformed 2-h PG was 1.41 (95%CI: 1.28–1.54) for all-cause mortality and 1.49 (1.31–1.70) for CVD mortality. Corresponding standardised hazard ratios for a standard deviation increase of 1 in log-transformed FPG were 1.22 (1.12–1.33) and 1.32 (1.18–1.49). The risk prediction based on these models showed that the relative risk

Table 2. Baseline characteristics of surveys analysed for this DECODA study

Study cohort	Funagata	Sao Paulo	Seattle	Mauritius	Fiji
Means of plasma glucose (mmol/l) [SD]					
Fasting	5.2 [0.6]	5.4 [0.9]	5.3 [1.0]	5.5 [†] (1.5)	5.5 [†] (1.9)
2-h	6.1 [2.1]	6.9 [†] [3.0]	7.8 [†] [2.6]	7.3 [†] [3.6]	7.2 [†] [4.0]
Age-standardised prevalence % (95% CI)					
IFG and/or IGT	11.7 (10.0–13.3)	18.0 (14.2–21.8)	32.9 (26.8–39.0)	22.1 (19.7–24.4)	18.8 (14.4–23.3)
Newly diagnosed DM	2.4 (1.6–3.1)	7.3 (4.9–9.7)	6.3 (4.0–8.7)	12.9 (11.1–14.7)	17.3 (13.1–21.5)
Previously diagnosed DM	4.2 (3.2–5.2)	11.4 (8.5–14.2)	16.6 (12.6–20.5)	9.4 (7.9–11.0)	13.5 (9.9–17.1)
All DM	6.6 (5.3–7.8)	18.7 (14.9–22.4)	22.9 (18.3–27.5)	22.3 (19.9–24.7)	30.8 (25.3–36.3)
Adjusted Means of CVD risk factors					
Age (years) ^a					
Normal glucose	57 (0.3)	59 [‡] (1)	50 [‡] (1)	43 [‡] (0.3)	42 [‡] (1)
IFG and/or IGT	63 (1)	60 [‡] (1)	56 [‡] (1)	47 [‡] (1)	47 [‡] (1)
Newly diagnosed DM	66 (1)	62 [‡] (2)	63 (2)	51 [‡] (1)	50 [‡] (1)
Previously diagnosed DM	65 (1)	63 (1)	62 [‡] (1)	55 [‡] (1)	52 [‡] (1)
BMI (kg/m ²) ^b					
Normal glucose	23.5 (0.1)	24.0 [‡] (0.2)	23.7 (0.2)	22.9 [‡] (0.1)	23.2 (0.2)
IFG and/or IGT	25.1 (0.3)	25.2 (0.4)	24.9 (0.3)	24.2 [‡] (0.2)	24.9 (0.4)
Newly diagnosed DM	25.9 (0.5)	26.1 (0.7)	26.5 (0.7)	24.9 (0.3)	25.6 (0.4)
Previously diagnosed DM	24.7 (0.4)	25.3 (0.5)	24.6 (0.4)	25.4 (0.3)	25.4 (0.5)
Blood pressure (mmHg) ^b					
Systolic					
Normal glucose	121 (0.4)	123 [‡] (1)	126 [‡] (1)	125 [‡] (0.4)	124 [‡] (1)
IFG and/or IGT	128 (1)	135 [‡] (2)	132 [‡] (1)	132 [‡] (1)	133 [‡] (2)
Newly diagnosed DM	130 (3)	136 (2)	136 (3)	137 [‡] (1)	142 [‡] (2)
Previously diagnosed DM	131 (2)	133 (3)	142 [‡] (2)	139 [‡] (2)	140 [‡] (2)
Diastolic					
Normal glucose	73 (0.3)	77 [‡] (1)	75 [‡] (1)	77 [‡] (0.3)	76 [‡] (0.5)
IFG and/or IGT	76 (1)	84 [‡] (1)	78 [‡] (1)	80 [‡] (0.5)	78 (1)
Newly diagnosed DM	77 (2)	82 (2)	81 (2)	82 [‡] (1)	85 [‡] (1)
Previously diagnosed DM	77 (1)	77 (1)	80 [‡] (1)	82 [‡] (1)	81 [‡] (1)
Total cholesterol (mmol/l) ^b					
Normal glucose	5.2 (0.03)	5.4 [‡] (0.1)	5.7 [‡] (0.1)	5.5 [‡] (0.03)	4.5 [‡] (0.06)
IFG and/or IGT	5.4 (0.1)	5.5 (0.1)	6.0 [‡] (0.1)	5.7 [‡] (0.1)	4.8 [‡] (0.1)
Newly diagnosed DM	5.4 (0.2)	5.9 (0.2)	6.1 [‡] (0.2)	6.2 [‡] (0.1)	4.9 [‡] (0.1)
Previously diagnosed DM	5.3 (0.1)	5.3 (0.2)	6.1 [‡] (0.1)	6.0 [‡] (0.1)	5.0 (0.2)

* Prevalence was age-standardised using the world standard population of subjects of 40 to 74 years of age

^aData are means (SEM) adjusted for sex. ^bData are means (SEM) adjusted for age and sex. [†] $p < 0.05$. Reference group

was Funagata for each glucose value among subjects without previously diagnosed diabetes. [‡] $p < 0.05$. Reference group was Funagata for each glucose category in individual risk factor. DM, diabetes mellitus

was 1.14 (1.05–1.25) for all-cause mortality and 1.24 (1.10–1.39) for CVD mortality when FPG increased from 7.0 to 8.0 mmol/l, corresponding to a 0.76 standard deviation increase in FPG. A similar 0.76 standard deviation increase in 2-h PG would correspond to an increase from 9 to 11.9 mmol/l, leading to a relative risk of 1.29 (1.18–1.41) and 1.35 (1.19–1.54) for all-cause mortality and CVD mortality respectively.

An increase in all-cause and CVD mortality coincided with an increasing deterioration of glucose metabolism from normal glucose tolerance to overt diabetes (Table 3). For the FPG criteria, the relative risk of death from CVD and all causes was statistically significant

only in the diabetic glucose range (FPG ≥ 7.0 mmol/l) compared with normoglycaemic individuals (FPG < 6.1 mmol/l) ($p < 0.001$). For the 2-h PG criteria the relative risk of death from all causes was statistically significant for the IGT range (7.8–11.0 mmol/l) ($p < 0.05$), while risk of CVD mortality only reached significance in the diabetic glucose range (2-h PG ≥ 11.1 mmol/l) ($p < 0.001$). Compared with the nested models, the inclusion of FPG did not significantly improve the prediction of death obtained from the model based on 2-h PG criteria alone ($\chi^2 = 0.43$ for all-cause mortality and $\chi^2 = 0.37$ for CVD mortality, 2df, both p values > 0.50). In contrast, the inclusion of the 2-h PG significantly im-

Fig. 1a, b. Individual (◆ or ■) and overall (■) hazard ratios and 95% CIs (lines) for all-cause mortality among subjects without previously diagnosed diabetes. Ratios are shown according to one standard deviation increase in natural log-transformed fasting (◆) (a) and 2-h (■) (b) plasma glucose concentrations in an OGTT, adjusting for age, sex, BMI, systolic blood pressure, total cholesterol and smoking status

Fig. 2a, b. Individual (◆ or ■) and overall (■) hazard ratios and 95% CIs (lines) for cardiovascular mortality among subjects without previously diagnosed diabetes. Ratios are shown according to one standard deviation increase in natural log-transformed fasting (◆) (a) and 2-h (■) (b) plasma glucose concentrations in an OGTT, adjusting for age, sex, BMI, systolic blood pressure, total cholesterol and smoking status

proved the prediction of death obtained from the model based on FPG criteria alone ($\chi^2=38.12$ for all-cause mortality and $\chi^2=24.08$ for CVD mortality, 2df, both p values <0.0001).

Cox proportional hazards analysis of the pooled data showed that participants with previously diagnosed diabetes had a higher risk of CVD and all-cause mortality than people in other glucose categories (Table 4). However the increased risk of death in previously diagnosed cases of diabetes was not statistically different from that in newly diagnosed cases. Diabetic subjects identified by 2-h PG alone (FPG <7.0 mmol/l and 2-h PG ≥ 11.1 mmol/l) had an equal risk of death from CVD and all causes to those screened by FPG (FPG ≥ 7.0 mmol/l). Subjects with IGR had a greater risk of death from CVD and all causes than those with normal glucose. However, the higher risk of death in cases of IGR was not statistically different from that in people with normal glucose concentrations.

Discussion

Several previous cohort studies which have included Asian subjects have shown that hyperglycaemia increases the risk for CVD morbidity and mortality [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 30]. The excess risk starts at glucose concentrations well below the threshold for the diagnosis of diabetes by current diagnostic criteria [13, 14, 15, 16, 17, 18, 19, 20, 21]. Our study, which was based on five cohorts with populations of Asian origin and had a 5-year median follow-up, showed that post-challenge glucose was an independent predictor of CVD and all-cause mortality among people without previously diagnosed diabetes. The association was graded with higher 2-h PG predicting higher mortality. When the data were analysed according to glucose categories, it was found that with regard to the prediction of premature death, post-challenge glucose (2-h PG)

Table 3. Multivariate hazard ratio (HR) with 95% CI of all-cause and cardiovascular mortality according to fasting and 2-h plasma glucose criteria

Fasting Plasma Glucose (mmol/l)		<6.1 (n=5547)	6.1–6.9 (n=462)	≥7.0 (n=297)	p value for linear trend for HR
All-cause mortality	* Mortality per 1000 person-years (numbers)	8.9 (8.8–8.9) (284)	13.1 (13.0–13.2) (47)	26.6 (26.3–26.8) (50)	
	Model 1	1	1.19 (0.87–1.64)	1.82 (1.31–2.52)	0.001
	Model 2	1	0.94 (0.68–1.31)	0.88 (0.59–1.32)	0.81
CVD mortality	* Mortality per 1000 person-years (numbers)	3.9 (3.9–4.0) (127)	7.3 (7.2–7.3) (26)	14.6 (14.5–14.8) (29)	
	Model 1	1	1.35 (0.86–2.08)	2.01 (1.30–3.11)	0.006
	Model 2	1	1.05 (0.67–1.65)	0.88 (0.51–1.51)	0.83
2-h Plasma glucose (mmol/l)		<7.8 (n=4753)	7.8–11.0 (n=1106)	≥11.1 (n=447)	p value for linear trend for HR
All-cause mortality	Mortality per 1000 person-years (numbers)	8.0 (7.9–8.0) (206)	10.5 (10.4–10.6) (87)	28.0 (27.8–28.2) (88)	
	Model 1	1	1.34 (1.03–1.74)	2.85 (2.16–3.75)	<0.001
	Model 3	1	1.35 (1.03–1.77)	3.03 (2.18–4.21)	<0.001
CVD mortality	Mortality per 1000 person-years (numbers)	3.5 (3.5–3.6) (91)	4.9 (4.8–4.9) (41)	15.6 (15.5–15.8) (50)	
	Model 1	1	1.27 (0.86–1.88)	3.21 (2.20–4.69)	<0.001
	Model 3	1	1.27 (0.86–1.88)	3.39 (2.14–5.37)	<0.001

^a Mortality was age-standardised using the world standard population of subjects of 30 to 89 years of age
 Model 1: adjusted for age, sex, cohort, BMI, systolic blood pressure, total cholesterol and smoking status

Model 2: adjusted for age, sex, cohort, BMI, systolic blood pressure, total cholesterol, smoking status and 2-h glucose criteria
 Model 3: adjusted for age, sex, cohort, BMI, systolic blood pressure, total cholesterol, smoking status and fasting glucose criteria

Table 4. Glucose categories and multivariate relative risks of all-cause and cardiovascular disease mortality The DECODA Study

Glucose categories (mmol/l)	Number of subjects	Mortality per 1000 person-years (95% CI) [number of deaths]	RR (95% CI)
All cause mortality			
FPG <6.1 and 2-h PG <7.8	4532	7.8 (7.7–7.9) [191]	1
FPG 6.1–6.9 and/or 2-h PG 7.8–11.0	1254	10.0 (9.9–10.1) [96]	1.26 (0.98–1.63)
FPG ≥7.0	297	26.6 (26.3–26.8) [50]	2.08 (1.48–2.91)
FPG <7.0 and 2-h PG ≥11.1	223	24.1 (23.9–24.4) [44]	2.80 (2.00–3.93)
Previously diagnosed DM	511	30.9 (30.7–31.1) [107]	3.22 (2.50–4.14)
CVD mortality			
FPG <6.1 and 2-h PG <7.8	4532	3.4 (3.4–3.4) [84]	1
FPG 6.1–6.9 and/or 2-h PG 7.8–11.0	1254	4.8 (4.7–4.9) [44]	1.19 (0.82–1.74)
FPG ≥7.0	297	15.6 (15.4–15.8) [29]	2.33 (1.47–3.69)
FPG <7.0 and 2-h PG ≥11.1	223	12.9 (12.7–13.0) [25]	3.42 (2.16–5.42)
Previously diagnosed DM	511	13.0 (12.9–13.2) [58]	3.57 (2.50–5.09)

Mortality was age-standardised using the world standard population of subjects of 30 to 89 years of age. Relative risk: adjusted for age, sex, cohort, BMI, systolic blood pressure, total

cholesterol and smoking status. RR, relative risk; FPG, fasting plasma glucose; 2-h PG, 2-hour plasma glucose; DM, diabetes mellitus

was superior to fasting glucose in these Asian populations, as previously shown for European populations [20, 21].

In our study the effect of FPG and/or 2-h PG associated with increased risks of all-cause and CVD mor-

tality was homogeneous across cohorts, although baseline mean values of CVD risk factors, the prevalence of diabetes and rates of CVD and all-cause mortality were different, being highest in Asian Indians, intermediate in Japanese immigrants and lowest in

ethnic Japanese people living in Japan. Moreover, the magnitude of the increased risk in the overall cohort was similar for FPG and 2-h PG. It showed a graded relation with CVD and all-cause mortality, independent of known CVD risk factors: The relative risk increased 14% for all-cause mortality and 24% for CVD mortality when FPG increased from 7.0 to 8.0 mmol/l. A corresponding increase of 2-h PG from 9.0 to 11.9 mmol/l increased all-cause mortality by 29% and CVD mortality by 35%. Similar graded relations between glucose concentrations and CVD and all-cause mortality have been found in white populations [13, 36].

Over an observation period which was half as long as that in Europe [20, 21], subjects with IGT based on 2-h PG concentrations (7.8–11.0 mmol/l) had a significantly greater risk of all-cause mortality than people with normal 2-h PG concentrations (<7.8 mmol/l). However, subjects with IFG based on FPG concentrations (6.1–6.9 mmol/l) did not have a greater risk of death than subjects with normal FPG (<6.1 mmol/l) in our study. It is possible that the excess risk of CVD mortality in subjects with IGT based on 2-h PG criteria (7.8–11.0 mmol/l) would have reached significance, if those with previous CVD events had been excluded from the analysis. In an 8-year follow-up of elderly non-diabetic Dutch people [16], the predictive ability of post-challenge glucose on CVD mortality dramatically improved and became statistically significant when subjects with previous CVD events were excluded. This could not be done in our study, because previous CVD events were defined by different criteria among the studies included in our analysis, so the validity of this information could not be assured.

Several recent reports from prospective epidemiological studies have suggested that CVD is more strongly associated with 2-h PG than with FPG [17, 19, 20, 21, 36, 37]. This stronger association with 2-h PG has also been reported for the degree of carotid atherosclerosis [38] and coronary atherosclerosis [39]. Although the mechanisms underlying these associations are not yet understood, it is noteworthy that the Insulin Resistance Atherosclerosis Study recently reported that higher acute-phase proteins, indicative of chronic sub-clinical inflammation, have a stronger relation to 2-h PG than to FPG [40] and insulin resistance [41]. Alternatively, increased 2-h PG concentrations could be a reflection of impaired early-phase glucose-stimulated insulin release, which could in turn increase oxidative stress [42], thus accounting for these findings.

Among people diagnosed with diabetes, either on the basis of FPG or 2-h PG concentrations, we showed that risk of death from CVD and all causes was higher than in people with the corresponding normal glucose categories. However, the excess risk observed in the diabetic FPG range disappeared after adjustment for 2-h PG. In contrast the prediction of death obtained

with 2-h PG was not influenced by FPG. These findings underscore reports from Europe [20, 21] that diagnostic criteria based on post-challenge glucose are more effective in predicting premature death than criteria based on fasting glucose.

Isolated post-challenge hyperglycaemia is common in elderly women [37] and among non-obese European [20, 21, 43] and southern hemisphere populations [30]. In the studies cited, subjects with isolated post-challenge hyperglycaemia also had an excess risk of CVD mortality. We found that 43% of all newly diagnosed cases of diabetes were detected by post-challenge glucose alone and that these subjects had an equal risk of death from CVD and all causes as people diagnosed by fasting glucose. Thus using only fasting glucose to screen for Type 2 diabetes in Asians will fail to detect nearly half of the persons with previously undiagnosed diabetes and a very high risk of premature death.

We found that subjects with IFG based on FPG criteria (6.1–6.9 mmol/l) had higher age-standardised all-cause and CVD mortality than those with IGT based on 2-h PG criteria (7.8–11.0 mmol/l). However, the excess risk of all-cause and CVD mortality in people with IFG based on FPG criteria, compared with that in people with normal FPG based on FPG criteria (<6.1 mmol/l) was largely dependent on the 2-h PG concentration. In contrast, the excess risk of all-cause and CVD mortality in participants with IGT based on 2-h PG criteria, compared with people with normal 2-h PG concentrations based on 2-h PG criteria (<7.8 mmol/l) was not influenced by FPG concentrations. Thus among non-diabetic Asians IGT based on 2-h PG criteria seems to be more effective than IFG based on FPG criteria in predicting premature death. This observation is consistent with findings for European populations [20, 21]. The clinical implications, however, are less clear. Three different trials [44, 45, 46] have shown that non-diabetic persons with a 2-h PG concentration in the IGT range can prevent progression to diabetes, but none of these trials showed a reduction of CVD events. The recent STOP-NIDDM trial showed a 49% risk reduction in CVD events in IGT patients treated with acarbose [47]. The British Fasting Hyperglycaemia Study did not show any benefit on the development of diabetes with lifestyle change among subjects with IFG [48]. In relation to screening for diabetes, the epidemiological data in combination with the clinical trials suggest that 2-h PG has a stronger prognostic implication than FPG, although both are highly correlated. It is therefore important to also identify people with isolated high 2-h PG values.

In the DECODE study [20], the excess risk of death from all causes was similar between people with isolated IGT and people with isolated IFG. The majority of subjects with IGT also had isolated IGT [20, 21]. These results emphasise the importance of identi-

fying non-diabetic subjects with IGT but normal fasting glucose. In our study, isolated IGT occurred in 71% of subjects with IGR. Because of the small number of deaths, we could not report separately the risk of death from all causes and CVD in the three IGR glucose categories.

In summary, post-challenge glucose was a graded and independent predictor of all-cause and CVD mortality among subjects without previously diagnosed diabetes in Asian (Japanese and Asian Indian) ethnic groups. While the OGTT is obviously needed to diagnose unrecognised diabetes and IGT, it is not ideal for screening purposes because it is time-consuming. Several risk scores [49, 50, 51, 52, 53] have been developed to identify individuals at high risk of having undiagnosed diabetes, but while the sensitivity and specificity of these risk scores may be stable between countries if applied to the same ethnic group, they are unlikely to perform equally well for different ethnic groups [54]. Against this background it is clear that the prevention of complications and premature death must start much earlier than the current cut-off points suggested for diabetes.

Acknowledgements. The DECODA study has been carried out with the support of grants from Novartis Pharma AG, Basel Switzerland, the Finnish Academy (grants 46558, 76502, 77618, 204274 and 205657). Japan Arteriosclerosis Prevention Fund (Japanese Ministry of Health, Welfare and Labour), Grant-in-Aid for Scientific Research (Japanese Ministry of Education, Culture, Sports, Science and Technology) and Japan Diabetes Foundation supported a fellowship for T. Nakagami. The DECODA Study was initially funded by Novo Nordisk, Bagsvaerd, Denmark.

Appendix

The DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia) has been carried out under the supervision of the International Diabetes Epidemiology Group.

Study centres included in this analysis are:

- Funagata Diabetes Studies: M. Tominaga, Department of Laboratory Medicine, Yamagata University, Yamagata, Japan
- Japanese American Community Diabetes Study: W.Y. Fujimoto, E.J. Boyko, M. McNeely, J. Shofer, D. Leonetti, University of Washington, Seattle, USA
- Japanese Brazilian Diabetes Study: L.J. Franco, S. Ferreira, S.G.A. Gimeno, Sao Paulo Federal University, Sao Paulo, Brazil
- Southern Hemisphere (Fiji, Mauritius) Non-Communicable Disease Study: P. Zimmet, G.K. Dowse, J. Shaw, K.G.M.M. Alberti, J. Tuomilehto, Australia, UK, Finland

Data analysis

T. Nakagami¹, Q. Qiao²

¹ Steno Diabetes Centre, Gentofte, Denmark

² Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland

Writing Committee

T. Nakagami^{1,2}, Q. Qiao³, J. Tuomilehto^{3,4}, B. Balkau⁵, N. Tajima⁶, G. Hu^{3,4}, K. Borch-Johnsen^{1,7}

¹ Steno Diabetes Centre, Gentofte, Denmark

² Diabetes Centre, Tokyo Women's Medical University, Tokyo, Japan

³ Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland

⁴ Department of Public Health, University of Helsinki, Helsinki, Finland

⁵ French National Institute for Health and Medical Research U258, Villejuif, France

⁶ Department of Internal Medicine (III), Jikei University School of Medicine, Tokyo, Japan

⁷ Faculty of Health Science, University of Aarhus, Aarhus, Denmark

References

1. Klein R (1995) Hyperglycemia and microvascular and macrovascular diseases in diabetes. *Diabetes Care* 18:258–268
2. Turner RC, Millns H, Neil HA et al. (1998) Risk factors for coronary artery disease in non-insulin-dependent diabetes (UKPDS 23). *BMJ* 316:823–828
3. Kuusisto J, Mykkanen L, Pyörälä K, Laakso M (1994) NIDDM and its metabolic control predict coronary heart disease in elderly subjects. *Diabetes* 43:960–967
4. Lehto S, Ronnema T, Pyörälä K, Laakso M (1996) Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. *Stroke* 27:63–68
5. Standl E, Balletshofer B, Dahl B et al. (1996) Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. *Diabetologia* 39:1540–1545
6. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K (1993) Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. *Diabetologia* 36:1175–1184
7. Groeneveld Y, Petri H, Hermans J, Springer MP (1999) Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. *Diabet Med* 16:2–13
8. Stratton IM, Adler AI, Neil HAW et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 321:405–412
9. Wei M, Gaskill SP, Haffner SM, Stern MP (1998) Effects of diabetes and level of glycaemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. *Diabetes Care* 21:1167–1172

10. Hanefeld M, Fischer S, Julius U et al. (1996) Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. *Diabetologia* 39:1577–1583
11. Knuiman MW, Welborn TA, Whittall DE (1992) An analysis of excess mortality rates for persons with non-insulin-dependent diabetes mellitus in Western Australia using the Cox proportional hazards regression model. *Am J Epidemiol* 135:638–648
12. Sasaki A, Uehara M, Horiuchi N, Hasegawa K (1983) A long-term follow-up study of diabetic patients in Osaka, Japan: mortality and causes of death. *Tohoku J Exp Med* 141[Suppl]:639–644
13. Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. *Diabetes Care* 22:233–240
14. Pyörälä K, Savolainen E, Lehtovirta E, Punsar S, Siltanen P (1979) Glucose tolerance and coronary heart disease: Helsinki policemen study. *J Chronic Dis* 32:373–376
15. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H (1983) Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. *BMJ* 287:867–870
16. De Vegt F, Dekker JM, Ruhe HG et al. (1999) Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. *Diabetologia* 42:926–931
17. Balkau B, Shipley MJ, Jarrett RJ et al. (1998) High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. *Diabetes Care* 21:360–367
18. Fujishima M, Kiyohara Y, Kato I et al. (1996) Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. *Diabetes* 45 [Suppl 3]:S14–S16
19. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. *Diabetes Care* 22:920–924
20. Anonymous (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group, European Diabetes Epidemiology Group. *Diabetes Epidemiology. Lancet* 354:617–621
21. Anonymous (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. DECODE Study Group, the European Diabetes Epidemiology Group. *Arch Intern Med* 161:397–405
22. King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. *Diabetes Care* 21:1414–1431
23. Amos AF, McCarty DJ, Zimmet P (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. *Diabet Med* 14 [Suppl]:S1–S85
24. Qiao Q, Nakagami T, Tuomilehto J et al. (2000) Comparison of the fasting and 2-h glucose criteria for diabetes in different Asian cohorts. DECODA Study Group; International Diabetes Epidemiology Group. *Diabetologia* 43:1470–1475
25. Nakagami T, Qiao Q, Tuomilehto J et al. (2002) The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype. DECODA Study Group. *Diabetes Epidemiology: Collaborative Analysis of Diagnostic criteria in Asia; International Diabetes Epidemiology Group. Diabetes Res Clin Pract* 55:35–43
26. Anonymous (2002) Cardiovascular risk profile assessment in glucose intolerant Asian individuals—an evaluation of the World Health Organization two-step strategy: the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia). *Diabet Med* 43:549–557
27. Fujimoto WY, Leonetti DL, Kinyoun JL et al. (1987) Prevalence of diabetes mellitus and impaired glucose tolerance among second-generation Japanese-American men. *Diabetes* 36:721–729
28. Fujimoto WY, Leonetti DL, Bergstrom RW, Kinyoun JL, Stolov WC, Wahl PW (1991) Glucose tolerance and diabetic complications among Japanese-American women. *Diabetes Res Clin Pract* 13:119–129
29. Gimeno SG, Ferreira SR, Franco LJ, Hirai AT, Matsumura L, Moisés RS (2002) Prevalence and 7-year incidence of Type II diabetes mellitus in a Japanese-Brazilian population: an alarming public health problem. *Diabetologia* 45:1635–1638
30. Shaw JE, Hodge AM, De Courten M, Chitson P, Zimmet PZ (1999) Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. *Diabetologia* 42:1050–1054
31. Dowse GK, Gareeboo H, Alberti KG et al. (1995) Changes in population cholesterol concentrations and other cardiovascular risk factor levels after five years of the non-communicable disease intervention programme in Mauritius. Mauritius Non-communicable Disease Study Group. *BMJ* 311:1255–1259
32. World Health Organization (1977) The manual of the international statistical classification of diseases, injuries and causes of death, 9th revision. WHO, Geneva
33. World Health Organization (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus. WHO, Geneva
34. Santos Silva I dos (1999) Cancer epidemiology: principles and methods. WHO IARC, Lyon
35. Fleiss JL (1993) The statistical basis of meta-analysis. *Stat Methods Med Res* 2:121–145
36. Anonymous (2003) Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular disease? DECODE Study Group. European Diabetes Epidemiology Group. *Diabetes Care* 26:688–696
37. Barrett-Connor E, Ferrarra A (1998) Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. *Diabetes Care* 21:1236–1239
38. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M (2000) Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. *Diabetes Care* 23:1830–1834
39. Kowalska I, Prokop J, Bachorzewska-Gajewska H et al. (2001) Disturbances of glucose metabolism in men referred for coronary arteriography. Postload glycemia as a predictor for coronary atherosclerosis. *Diabetes Care* 24:897–901
40. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM (2002) C-reactive protein is more strongly related to post-glucose load than with to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. *Diabet Med* 19:939–943
41. Festa A, D'Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). *Circulation* 102:42–47

42. Ceriello A (2003) The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. *Diabetologia* 46 [Suppl 1]:M9–M16
43. Anonymous (1999) Consequence of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). *Diabetes Care* 22:1667–1671
44. Pan XR, Li GW, Hu YH et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* 20:537–544
45. Tuomilehto J, Lindström J, Eriksson JG et al. (2001) Prevention of type2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 344:1343–1350
46. Knowler WC, Barrett-Connor E, Fowler SE et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. *N Engl J Med* 346:393–403
47. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. *JAMA* 290:486–494
48. Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC (1997) The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. *Metabolism* 46 [Suppl 1]:50–55
49. Herman WH, Smith PJ, Thompson TJ, Engelgau MM, Aubert RE (1995) A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes. *Diabetes Care* 18:382–387
50. Ruige JB, Neeling JN de, Kostense PJ, Bouter LM, Heine RJ (1997) Performance of an NIDDM screening questionnaire based on symptoms and risk factors. *Diabetes Care* 20:491–496
51. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ (2000) Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. *Diabetes Metab Res Rev* 16:164–171
52. Lindström J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. *Diabetes Care* 26:725–731
53. Glümer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K (2004) A Danish diabetes risk score for targeted screening. *Inter 99* (6). *Diabetes Care* (in press)
54. Glümer C, Borch-Johnsen K, Jorgensen T, Colagiuri S (2003) Can screening algorithms for diabetes be applied across populations? *Diabetes Metab* 29 [Suppl 5]:S22